1. mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) 2. recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 3. alt/ast \> 5 times the upper limit of normal. 4. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance \<30 ml/min) 5. history of or evidence of qt prolongation on ecg examination 6. history of psoriasis or porphyria 7. absolute neutrophil count (anc) is \< 2000 mm3 8. pregnancy 9. history of hepatic disease, hepatitis c infection, or alcoholism 10. history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency 11. concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. 12. anticipated transfer to another hospital which is not a study site within 72 hours. 13. allergy to any study medication 14. known to be immunocompromised by disease or treatment for existing disease

1. mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) 2. recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 3. alt/ast \> 5 times the upper limit of normal. 4. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance \<30 ml/min) 5. history of or evidence of qt prolongation on ecg examination 6. history of psoriasis or porphyria 7. absolute neutrophil count (anc) is \< 2000 mm3 8. pregnancy 9. history of hepatic disease, hepatitis c infection, or alcoholism 10. history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency 11. concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. 12. anticipated transfer to another hospital which is not a study site within 72 hours. 13. allergy to any study medication 14. known to be immunocompromised by disease or treatment for existing disease

mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 alt/ast > 5 times the upper limit of normal. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance <30 ml/min) history of or evidence of qt prolongation on ecg examination history of psoriasis or porphyria absolute neutrophil count (anc) is < 2000 mm3 pregnancy history of hepatic disease, hepatitis c infection, or alcoholism history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. anticipated transfer to another hospital which is not a study site within 72 hours. allergy to any study medication known to be immunocompromised by disease or treatment for existing disease

mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 alt/ast > 5 times the upper limit of normal. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance <30 ml/min) history of or evidence of qt prolongation on ecg examination history of psoriasis or porphyria absolute neutrophil count (anc) is < 2000 mm3 pregnancy history of hepatic disease, hepatitis c infection, or alcoholism history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. anticipated transfer to another hospital which is not a study site within 72 hours. allergy to any study medication known to be immunocompromised by disease or treatment for existing disease

1. mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) 2. recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 3. alt/ast > 5 times the upper limit of normal. 4. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance <30 ml/min) 5. history of or evidence of qt prolongation on ecg examination 6. history of psoriasis or porphyria 7. absolute neutrophil count (anc) is < 2000 mm3 8. pregnancy 9. history of hepatic disease, hepatitis c infection, or alcoholism 10. history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency 11. concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. 12. anticipated transfer to another hospital which is not a study site within 72 hours. 13. allergy to any study medication 14. known to be immunocompromised by disease or treatment for existing disease

1. mild covid-19 disease (minor clinical symptoms, imaging does not show signs of lung inflammation) 2. recent history of or any in-hospital exposure to investigational medications targeting covid-19, or concurrent participation in a clinical trial targeting covid-19 3. alt/ast > 5 times the upper limit of normal. 4. moderate renal insufficiency (creatinine clearance 30-50 ml/min) or stage 4 severe chronic kidney disease or requiring dialysis (i.e. creatinine clearance <30 ml/min) 5. history of or evidence of qt prolongation on ecg examination 6. history of psoriasis or porphyria 7. absolute neutrophil count (anc) is < 2000 mm3 8. pregnancy 9. history of hepatic disease, hepatitis c infection, or alcoholism 10. history of g-6-pd (glucose-6-phosphate dehydrogenase) deficiency 11. concomitant use of the following medications: atazanavir, dasatinib, neratinib, ozanimod, pazopanib, rilpivirine, siponimod, and/or tizanidine. 12. anticipated transfer to another hospital which is not a study site within 72 hours. 13. allergy to any study medication 14. known to be immunocompromised by disease or treatment for existing disease